There is no one-size-fits all treatment for Parkinsons. Rather, treatment should be tailored to an individuals symptoms via a shared decision-making process with your healthcare provider Continue reading →

With medical marijuana now legalized in 38 states and the District of Columbia, there is strong interest in its therapeutic properties. Researchers are testing marijuana, which is also called cannabis, as a treatment for many illnesses and diseases, including Parkinson's disease (PD). Continue reading →

The concept of 'idiopathic' Parkinson's disease (PD) as a single entity has been challenged with the identification of several clinical subtypes, pathogenic genes and putative causative environmental agents. In addition to classic motor symptoms, non-motor manifestations (such as rapid eye movement sleep disorder, anosmia, constipation and depression) appear at prodromic/premotor stage and evolve, along with cognitive impairment and dysautonomia, as the disease progresses, often dominating the advanced stages of the disease. The key molecular pathogenic mechanisms include -synuclein misfolding and aggregation, mitochondrial dysfunction, impairment of protein clearance (associated with deficient ubiquitin-proteasome and autophagy-lysosomal systems), neuroinflammation and oxidative stress. Continue reading →

Overview Wolff-Parkinson-White Syndrome - Patrick Tchou, MD What is Wolff-Parkinson-White Syndrome (WPW)? Normally, the heartbeat begins at the sinoatrial (SA) node, located in your right atrium. Continue reading →

IMAC Holdings, Inc. BRENTWOOD, Tenn., Sept Continue reading →

SAN CARLOS, Calif.--(BUSINESS WIRE)--CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it has begun dosing patients in a Phase 2a clinical trial with CST-2032, a novel, oral beta-2 adrenoceptor (2-AR) agonist. The goal of the study is to evaluate the effects of CST-2032 on cognition and mood in patients with mild cognitive impairment or mild dementia due to either Parkinsons or Alzheimers disease. CST-2032 is administered in combination with CST-107, a -AR blocker, to minimize known side effects of 2-AR agonists. Continue reading →

Its not a run, its a walk. Its really a fun event Continue reading →

Fast-track status is granted for frontotemporal dementia, next to the existing designation for traumatic spinal cord injury GELEEN, Netherlands, Sept. Continue reading →